Linked Life Data

9572994

Source:http://linkedlifedata.com/resource/pubmed/id/9572994

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1998-6-12
pubmed:abstractText
In 105 consecutive patients with de novo acute myeloid leukemia (French-American-British M3 excluded), we compared prospectively the risk of bleeding complications, the number of platelet and red blood cell transfusions administered, and the costs of transfusions using two different prophylactic platelet transfusion protocols. Two hundred sixteen cycles of induction or consolidation chemotherapy and 3,843 days of thrombocytopenia less than 25 x 10(9)/L were evaluated. At the start of the study, each of the 17 participating centers decided whether they would use a 10 x 10(9)/L prophylactic platelet transfusion trigger (group A/8 centers) or a 20 x 10(9)/L trigger (group B/9 centers). Bleeding complications (World Health Organization grade 2-4) during treatment cycles were comparable in the two groups: 20 of 110 (18%) in group A and 18 of 106 (17%) in group B (P = .8). Serious bleeding events (grade 3-4) were generally not related to the patient's platelet count but were the consequence of local lesions and plasma coagulation factor deficiencies due to sepsis. Eighty-six percent of the serious bleeding episodes occurred during induction chemotherapy. No patient died of a bleeding complication. There were no significant differences in the number of red blood cell transfusions administered between the two groups, but there were significant differences in the number of platelet transfusions administered per treatment cycle: pooled random donor platelet concentrates averaged 15.4 versus 25.4 (P < .01) and apheresis platelets averaged 3.0 versus 4.8 (P < .05) for group A versus group B, respectively. This resulted in the cost of platelet therapy being one third lower in group A compared with group B without any associated increase in bleeding risk.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0006-4971
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
3601-6
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:9572994-Acute Disease, pubmed-meshheading:9572994-Adolescent, pubmed-meshheading:9572994-Adult, pubmed-meshheading:9572994-Aged, pubmed-meshheading:9572994-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:9572994-Cost-Benefit Analysis, pubmed-meshheading:9572994-Erythrocyte Transfusion, pubmed-meshheading:9572994-Hemorrhage, pubmed-meshheading:9572994-Humans, pubmed-meshheading:9572994-Leukemia, Myeloid, pubmed-meshheading:9572994-Middle Aged, pubmed-meshheading:9572994-Platelet Count, pubmed-meshheading:9572994-Platelet Transfusion, pubmed-meshheading:9572994-Plateletpheresis, pubmed-meshheading:9572994-Prospective Studies, pubmed-meshheading:9572994-Risk, pubmed-meshheading:9572994-Safety, pubmed-meshheading:9572994-Severity of Illness Index, pubmed-meshheading:9572994-Thrombocytopenia
pubmed:year
1998
pubmed:articleTitle
Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
pubmed:affiliation
5th Medical Department and Institute of Medical Oncology and Hematology, Nürnberg, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Multicenter Study